Incyte Corp (NASDAQ:INCY)

99.36
Delayed Data
As of May 22
 +0.68 / +0.69%
Today’s Change
62.48
Today|||52-Week Range
104.81
+13.79%
Year-to-Date
Why Gilead's Remdesivir Might Not Be the Mega-Moneymaker Some Think It Will Be
May 17 / MotleyFool.com - Paid Partner Content
Why Geron Stock Soared 23.4% Today
May 15 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close98.68
Today’s open97.72
Day’s range97.53 - 101.75
Volume118,564
Average volume (3 months)1,864,504
Market cap$21.6B
Data as of 6:55pm ET, 05/22/2020

Growth & Valuation

Earnings growth (last year)+299.90%
Earnings growth (this year)-160.78%
Earnings growth (next 5 years)+32.00%
Revenue growth (last year)+14.71%
P/E ratioNM
Price/Sales8.80
Price/Book8.27

Competitors

 Today’s
change
Today’s
% change
ALXNAlexion Pharmaceutic...+0.42+0.42%
SGENSeattle Genetics Inc+1.58+1.02%
ALNYAlnylam Pharmaceutic...-1.44-1.02%
GLPGGalapagos NV-3.57-1.75%
Data as of 4:00pm ET, 05/22/2020

Financials

Next reporting dateAugust 4, 2020
EPS forecast (this quarter)$0.59
Annual revenue (last year)$2.2B
Annual profit (last year)$446.9M
Net profit margin20.70%

Profile

Sector
Health Technology
Industry
Biotechnology
No executives to display
Corporate headquarters
Wilmington, Delaware

Forecasts